Baharak Moshiree, MD, MSc, FACG, AGAF
Professor of Medicine
Director of University of North Carolina, Department of Medicine
Atrium Health Gastroenterology and Hepatology
Satish Rao, MD, PhD, FRCP (LON), FACG, AGAF J. Harold Harrison, MD, Distinguished University Chair in Gastroenterology Professor of Medicine Augusta University Medical Center Augusta, GA
This CME monograph is targeted at primary care physicians and allied health care providers.
The goal of this monograph will focus on emerging treatment updates, reviewing current treatment guidelines, and advances in the management of irritable bowel syndrome (IBS).
After completing this activity, participants should be better able to:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and the Gi Health Foundation. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this journal supplement for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP (American Academy of Family Physicians) Accreditation:
The AAFP has reviewed IBS Prime Journal Supplement and deemed it acceptable for up to 2.00 Medical Journals, Self-Study AAFP Prescribed credit. Term of Approval is from 01/01/2021 to 12/31/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement:
Nursing Accreditation Statement:
Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This program has been approved for 1.0 contact hour.
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
All additional planning committee members, staff and reviewers of The GI Health Foundation and Purdue University College of Pharmacy have no relationships to disclose.
Satish Rao discloses that he is on advisory boards for In Control Medical, Ironwood Pharmaceuticals, Neurogut, Inc., Progenity, Quin-Tron, Takeda Pharmaceuticals, Valeant Pharmaceuticals, and Vibrant; and that he has received research grants from Progenity, Valeant Pharmaceuticals, and Vibrant.
Baharak Moshiree discloses that he is on advisory boards for Salix and Takeda; that he has received research grants from Allergan, Progenity, Salix, Takeda, and Urovant; and that he participates in speakers bureaus for QOL Medical, Salix, and Takeda. Julianne Messick, PharmD (medical writer) discloses she has no conflicts of interest.
This program is supported by educational grants from Salix Pharmaceuticals and Takeda Pharmaceuticals U.S.A., Inc.